Provided by Tiger Trade Technology Pte. Ltd.

Cocrystal Pharma, Inc.

1.15
-0.0200-1.71%
Post-market: 1.13-0.0200-1.74%19:36 EDT
Volume:84.75K
Turnover:98.19K
Market Cap:22.15M
PE:-1.51
High:1.21
Open:1.19
Low:1.10
Close:1.17
52wk High:2.67
52wk Low:0.7600
Shares:19.26M
Float Shares:11.85M
Volume Ratio:1.14
T/O Rate:0.72%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.7613
EPS(LYR):-0.7822
ROE:-311.68%
ROA:-96.07%
PB:21.22
PE(LYR):-1.47

Loading ...

Cocrystal Pharma Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 15

Cocrystal Pharma Q1 EPS $(0.17) Misses $(0.15) Estimate, Sales $225.000K

Benzinga Earnings
·
May 15

Cocrystal Pharma wins FDA Fast Track designation for norovirus drug CDI-988

Reuters
·
May 15

Cocrystal Pharma Inc expected to post a loss of 15 cents a share - Earnings Preview

Reuters
·
May 11

Cocrystal Pharma publishes CDI-988 norovirus antiviral presentation slides from ICAR 2026

Reuters
·
May 01

Cocrystal Pharma advances CDI-988 into Phase 1b norovirus human challenge trial

Reuters
·
May 01

Cocrystal Pharma files $150M mixed securities shelf

TIPRANKS
·
Apr 24

BRIEF-Cocrystal Pharma Inc - Files To Offer Up To $150 Million In Securities - SEC Filing

Reuters
·
Apr 24

Cocrystal Pharma Inc - Files to Offer up to $150 Mln in Securities - SEC Filing

THOMSON REUTERS
·
Apr 24

Cocrystal Pharma publishes investor presentation on antiviral pipeline for norovirus, influenza, coronaviruses

Reuters
·
Apr 16

Why Cocrystal Pharma Shares Are Cooling Off Monday?

Benzinga
·
Apr 06

BUZZ-Cocrystal Pharma rises as FDA fast-tracks oral norovirus drug

Reuters
·
Apr 02

Cocrystal Pharma Receives FDA Fast Track Designation for Cdi-988 for Norovirus Infection Treatment and Preventive

THOMSON REUTERS
·
Apr 02

Cocrystal Pharma starts Phase 1b human challenge trial of norovirus drug CDI-988

Reuters
·
Apr 01

Cocrystal Pharma Q4 EPS $(0.17) Beats $(0.21) Estimate

Benzinga Earnings
·
Mar 31

Cocrystal Pharma 2025 net loss narrows as R&D expenses fall

Reuters
·
Mar 31

BRIEF-Cocrystal Pharma FY Net Income USD -8.831 Million

Reuters
·
Mar 31

Cocrystal Pharma Reports 2025 Financial Results and Provides Updates on Its Antiviral Drug-Development Programs

THOMSON REUTERS
·
Mar 31

Cocrystal Pharma FY Operating Expenses USD 9.019 Million

THOMSON REUTERS
·
Mar 31

Cocrystal Pharma Inc expected to post a loss of 17 cents a share - Earnings Preview

Reuters
·
Mar 27